Bristol-Myers, Oncolys enter into licensing agreement for HIV compound
Under the agreement, Oncolys may receive up to $286m as well as upfront, development, regulatory and sales milestone payments. In addition, Oncolys is eligible to receive tiered royalties
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.